DK0655055T3 - Tachykininantagonister - Google Patents

Tachykininantagonister

Info

Publication number
DK0655055T3
DK0655055T3 DK93919974T DK93919974T DK0655055T3 DK 0655055 T3 DK0655055 T3 DK 0655055T3 DK 93919974 T DK93919974 T DK 93919974T DK 93919974 T DK93919974 T DK 93919974T DK 0655055 T3 DK0655055 T3 DK 0655055T3
Authority
DK
Denmark
Prior art keywords
compounds
tachykinin antagonists
nonpeptides
tachykinins
allergies
Prior art date
Application number
DK93919974T
Other languages
Danish (da)
English (en)
Inventor
Martyn Clive Pritchard
David Christopher Horwell
Edward Roberts
William Howson
David Charles Rees
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0655055T3 publication Critical patent/DK0655055T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK93919974T 1992-08-13 1993-08-12 Tachykininantagonister DK0655055T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93025292A 1992-08-13 1992-08-13
US9726493A 1993-07-23 1993-07-23
PCT/US1993/007552 WO1994004494A1 (fr) 1992-08-13 1993-08-12 Antagonistes de tachykinine

Publications (1)

Publication Number Publication Date
DK0655055T3 true DK0655055T3 (da) 2001-01-02

Family

ID=26793050

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93919974T DK0655055T3 (da) 1992-08-13 1993-08-12 Tachykininantagonister

Country Status (13)

Country Link
US (4) US5594022A (fr)
EP (2) EP1000930A3 (fr)
JP (1) JP3507494B2 (fr)
AT (1) ATE197793T1 (fr)
AU (1) AU687754B2 (fr)
CA (1) CA2140640A1 (fr)
DE (1) DE69329712T2 (fr)
DK (1) DK0655055T3 (fr)
ES (1) ES2153841T3 (fr)
GR (1) GR3035372T3 (fr)
NZ (1) NZ255721A (fr)
PT (1) PT655055E (fr)
WO (1) WO1994004494A1 (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659409A3 (fr) * 1993-11-23 1995-08-09 Pfizer Antagonistes de la substance P pour l'inhibition de l'angiogénése.
NZ270985A (en) 1994-04-29 1997-06-24 Lilly Co Eli Substituted benzimidazole derivatives; medicaments and preparation of medicaments
WO1995033744A1 (fr) * 1994-06-06 1995-12-14 Warner-Lambert Company Antagonistes du recepteur de la tachykinine (nk1)
US5597845A (en) * 1994-06-20 1997-01-28 Merrell Pharmaceuticals Inc. Substituted alkyldiamine derivatives
MX9700271A (es) 1994-07-12 1997-05-31 Lilly Co Eli Antagonistas heterociclicos del receptor de taquinicina.
US5554641A (en) * 1995-03-20 1996-09-10 Horwell; David C. Nonpeptides as tachykinin antagonists
WO1996041633A1 (fr) * 1995-06-08 1996-12-27 Eli Lilly And Company Methodes de traitement des rhumes et des rhinites allergiques
AU5966096A (en) * 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
JP2000514047A (ja) * 1996-06-26 2000-10-24 ワーナー―ランバート・コンパニー 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用
ES2253782T3 (es) * 1996-08-22 2006-06-01 Warner-Lambert Company Llc Antagonistas de receptor de bombesina no peptidicos.
CA2268399C (fr) * 1996-10-31 2008-08-19 Harbor Branch Oceanographic Institution, Inc. Composes et compositions inflammatoires antineurogenes et methodes d'utilisation
BR9811819A (pt) * 1997-08-06 2000-08-15 Lilly Co Eli 2-acilaminopropanaminas como antagonistas receptores de taquicinina
TR200000291T2 (tr) 1997-08-06 2000-07-21 Eli Lilly And Company Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
US6291501B1 (en) 1998-02-20 2001-09-18 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
JP2002511467A (ja) * 1998-04-15 2002-04-16 ワーナー−ランバート・カンパニー ベンゾフラニルメチルカルバメートｎｋ１拮抗物質のプロドラッグ
JP2003523921A (ja) 1998-06-12 2003-08-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
US6472418B1 (en) 1998-12-18 2002-10-29 Warner-Lambert Company Non-peptide NK1 receptors antagonists
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US6372440B2 (en) 1999-03-10 2002-04-16 Magnesium Diagnostics, Inc. Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
EP1163262B1 (fr) * 1999-03-23 2011-05-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Derives de phenylalanine
DE19922317A1 (de) * 1999-05-14 2000-11-16 Goedecke Ag Verfahren zur Herstellung von (R)-N-[(Benzo[b]furan-2-yl)-alkoxycarbonyl]- tryptophanalkylestern
DE19922316A1 (de) * 1999-05-14 2000-11-16 Goedecke Ag Verfahren zur Herstellung von (R)-N-[(Benzo[b]furan-2-yl)-alkoxycarbonyl]-tryptophanalkylestern
DE19922315A1 (de) * 1999-05-14 2000-11-16 Goedecke Ag Verfahren zur Herstellung von (R)-N-[(Benzo[b] furan-2-yl)-alkoxycarbonyl]- tryptophanalkylestern
IT1306165B1 (it) * 1999-07-05 2001-05-30 Innova Ltd Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
GB9927125D0 (en) 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
AU2370801A (en) * 1999-12-22 2001-07-03 Warner-Lambert Company Non peptide tachykinin receptor antagonists
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
NZ521028A (en) 2000-03-16 2004-07-30 F Carboxylic acid derivatives as IP antagonists
ATE367811T1 (de) * 2000-06-12 2007-08-15 Univ Rochester Methode zur behandlung von hitzewallungen, durch verwendung eines tachikinin-rezeptor antagonisten
NZ523774A (en) 2000-08-01 2004-09-24 Sod Conseils Rech Applic Imidazolyl derivatives
GB2369117A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
US6337069B1 (en) * 2001-02-28 2002-01-08 B.M.R.A. Corporation B.V. Method of treating rhinitis or sinusitis by intranasally administering a peptidase
US6709651B2 (en) 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
MY130373A (en) 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
GB0215392D0 (en) * 2002-07-03 2002-08-14 Glaxo Group Ltd Chemical compounds
FR2847471B1 (fr) * 2002-11-25 2006-12-29 Expanscience Lab Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament
CA2522195A1 (fr) * 2003-04-15 2004-10-28 Warner-Lambert Company Llc Derives bicycliques [b]-fusionnes de proline et leur utilisation pour traiter des etats arthritiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006102308A2 (fr) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Antagonistes de bêta-lactamyl vasopressine v1b
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
WO2006135783A2 (fr) * 2005-06-10 2006-12-21 Wisconsin Alumni Research Foundation Compositions et methodes pour moduler une angiogenese
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
AU2006270039B2 (en) 2005-07-19 2013-07-04 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
EP2145884B1 (fr) 2007-04-02 2014-08-06 Msd K.K. Dérivé d'indoledione
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20090035279A (ko) * 2007-10-05 2009-04-09 경희대학교 산학협력단 위장관 손상 예방 및 치료용 조성물
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2429295B1 (fr) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
EP2429293B1 (fr) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company FORMES CRISTALLINES DE (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN -6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE ET LEURS UTILISATIONS
WO2010132442A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
PL2587919T3 (pl) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Sposoby leczenia zespołu stresu pourazowego
CA2805265A1 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
CA2807307C (fr) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
US10653681B2 (en) * 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3706747A4 (fr) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
MX2022003933A (es) * 2019-10-02 2022-04-25 Domain Therapeutics Antagonistas del receptor ep4 de prostaglandina e2 (pge2).

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636667A (fr) * 1963-08-28
US4000297A (en) * 1971-05-18 1976-12-28 Rotta Research Laboratorium S.P.A. N-p-chlorobenzoyl tryptophane, salts and compositions thereof
JPS5826745B2 (ja) * 1976-06-01 1983-06-04 三共株式会社 Ｎα−アシル−α−Ｌ−アミノ酸アニリド化合物
US4727189A (en) * 1985-01-22 1988-02-23 G. D. Searle & Co. Substituted tyrosyl alanine dipeptide amides
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
WO1989010355A1 (fr) * 1988-04-05 1989-11-02 Abbott Laboratories Derives de tryptophan utilises comme antagonistes cck
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
US5138061A (en) * 1989-08-04 1992-08-11 Biochem Pharma Inc. Thioacylating reagents
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
ATE208400T1 (de) * 1990-08-31 2001-11-15 Warner Lambert Co Pro-medikamente für cck-antagonisten
DE69208088T2 (de) * 1991-07-05 1996-11-14 Merck Sharp & Dohme Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
WO1993001169A2 (fr) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Composes aromatiques, compositions pharmaceutiques les contenant et leur utilisation therapeutique
EP0593615B1 (fr) * 1991-07-10 1996-01-31 MERCK SHARP & DOHME LTD. Composes aromatiques, compositions les contenant et leurs utilisations therapeutiques
US5328927A (en) * 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
JPH05294915A (ja) * 1992-04-21 1993-11-09 Yamanouchi Pharmaceut Co Ltd タキキニン拮抗剤
US5554627A (en) * 1992-10-30 1996-09-10 Merck, Sharp & Dohme Ltd. Tachykinin antagonists
WO1994025482A1 (fr) * 1993-04-23 1994-11-10 Evans Herbert J Polypeptides comprenant des groupes contraignant la conformation qui sont adjacents a un site d'interaction proteine-proteine
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
WO1995033744A1 (fr) * 1994-06-06 1995-12-14 Warner-Lambert Company Antagonistes du recepteur de la tachykinine (nk1)
US5565568A (en) * 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists

Also Published As

Publication number Publication date
US5594022A (en) 1997-01-14
JP3507494B2 (ja) 2004-03-15
ATE197793T1 (de) 2000-12-15
CA2140640A1 (fr) 1994-03-03
ES2153841T3 (es) 2001-03-16
DE69329712D1 (de) 2001-01-04
EP1000930A2 (fr) 2000-05-17
AU687754B2 (en) 1998-03-05
EP0655055A1 (fr) 1995-05-31
AU5005593A (en) 1994-03-15
NZ255721A (en) 1997-06-24
US5856354A (en) 1999-01-05
JPH08500361A (ja) 1996-01-16
WO1994004494A1 (fr) 1994-03-03
US5981755A (en) 1999-11-09
GR3035372T3 (en) 2001-05-31
US5716979A (en) 1998-02-10
DE69329712T2 (de) 2001-04-12
EP1000930A3 (fr) 2003-10-29
EP0655055B1 (fr) 2000-11-29
PT655055E (pt) 2001-03-30

Similar Documents

Publication Publication Date Title
ATE197793T1 (de) Tachykinin antagonistes
ATE206710T1 (de) Tachykinin (nk1) rezeptor antagonisten
MY131442A (en) Excitatory amino acid receptor antagonists
EA200200647A1 (ru) АГОНИСТЫ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
BG66103B1 (bg) Кондензирани пиролокарбазоли
TW200612985A (en) Immunoglobulins
DE69425267D1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
EA200300807A1 (ru) Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE69926254D1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
AU6995391A (en) Intermediates in the preparation of novel bicyclic esters and amides useful as specific 5-ht3 antagonists
IL196900A0 (en) Autologous t-cell vaccines compositions
ES2160103T3 (es) Peptidos que tienen actividad antagonista de taquiquinina.
DE60135158D1 (de) Antagonisten des ige-rezeptors
DE69504198D1 (de) Substituierte alkyldiaminderivate und ihre verwendung als tachykinin antagonisten
NO881991L (no) Fremgangsmaate for fremstilling av nye substituerte silylalkylenaminer.
WO2001074997A3 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 11, et polynucleotide codant pour ce polypeptide